Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Cardiometabolic Disease Market: By Type: Chronic/Congestive Heart Failure, Hypertension, Others; By Treatment; By Dosage; By Route of Administration; By Distribution Channel; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Cardiometabolic Disease Market Outlook

The global cardiometabolic disease market reached a value of about USD 111 billion in 2021. The industry is further expected to grow at a CAGR of about 3.90% in the forecast period of 2022-2027 to reach a value of around USD 134.4 billion by 2027.

 

Global Cardiometabolic Disease Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to be Among the Significant Regional Markets for Cardiometabolic Disease

North America is one of the dominant regions in the global cardiometabolic diseases industry due to major key players, growing investment in research and development activities, high healthcare expenditure, and a well-developed healthcare sector. The increasing epidemic, the growing uptake of unhealthy diets, and a largely sedentary lifestyle further augment the market growth in North America. Also, the demand for advanced and sophisticated treatments is likely to fuel the global cardiometabolic disease industry in the coming years.

The Asia Pacific region is expected to witness growth during the forecast period due to the increasing research and development activities, rising investment in the healthcare sector and growing government support, and the surging incidence of cardiovascular diseases. Also, increasing awareness among European customers about cardiometabolic disease and an increasing number of healthcare industries are among the other important factors responsible for the market growth.

 

Market Segmentations

Cardiometabolic illnesses are a group of metabolic diseases that increase the risk of cardiovascular disease in people. These conditions include hypertension, central obesity, insulin resistance, dyslipidemia, and glucose tolerance. As a result of these disorders, patients are more likely to develop stroke, diabetes, or various types of heart disease. Cardiometabolic diseases can be caused by a combination of hereditary and environmental factors.

 

Global Cardiometabolic Disease Market by Segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By type, the market includes:

  • Chronic/Congestive Heart Failure
  • Hypertension
  • Type 2 Diabetes
  • Obesity

The various treatments in the market are:

  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Diuretics
  • Glucophage
  • Liposuction

Based on dosage, the market is divided into:

  • Tablet
  • Injection

Based on the route of administration, the market can be divided into:

  • Oral
  • Intravenous

The several distribution channels of the market are:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

The end-uses of the market are:

  • Clinic
  • Hospital
  • Homecare Settings

The regional markets for the cardiometabolic disease industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

Global Cardiometabolic Disease Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Growing Demand for Healthy Lifestyle Augmenting the Market Growth

The significant factors influencing the global market growth include the growing demand for a healthy lifestyle as it is crucial for maintenance. Due to rapidly changing lifestyles, food habits, and genetic predisposition, there is a rise in various diseases, such as diabetes, high cholesterol, cardiovascular disease, hypertension, and others. Higher consumption of fast food due to changing lifestyles results in a higher cases of obesity and increase in the usage of biomarkers for diagnostic and risk assessment procedures, which are the major factors influencing the market growth. Also, the increasing awareness and government initiatives on public healthcare will further fuel the market growth. The rising number of patients adopting pharmaceuticals and therapeutics due to the proliferation of digital modes of drug delivery and innovations and advancements in technologies used for the drug delivery in the healthcare industry are the drivers that will expand the cardiometabolic diseases market. Moreover, an increase in the proliferation of AI technology in the healthcare industry resulting in improved support services will act as a market driver and accelerate the growth rate. The rise in research and development (R&D) activities and emerging markets will benefit the cardiometabolic diseases industry.

 

Key Players in the Global Cardiometabolic Disease Market

The report gives a detailed analysis of the following key players in the global cardiometabolic disease industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Novartis AG
  • Cardax, Inc.
  • Novo Nordisk A/S
  • Bayer AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Industry Opportunities and Challenges  
8    Global Cardiometabolic Disease Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Cardiometabolic Disease Historical Market (2017-2021) 
    8.3    Global Cardiometabolic Disease Market Forecast (2022-2027)
    8.4    Global Cardiometabolic Disease Market by Type
        8.4.1    Chronic/Congestive Heart Failure
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Hypertension
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Type 2 Diabetes
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Obesity
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
    8.5    Global Cardiometabolic Disease Market by Treatment
        8.5.1    Angiotensin Converting Enzyme (ACE) Inhibitors
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Diuretics
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Glucophage
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Liposuction 
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
    8.6    Global Cardiometabolic Disease Market by Dosage
        8.6.1    Tablet
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Injection
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
    8.7    Global Cardiometabolic Disease Market by Route of Administration
        8.7.1    Oral
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2021)
            8.7.1.3    Forecast Trend (2022-2027)
        8.7.2    Intravenous
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2021)
            8.7.2.3    Forecast Trend (2022-2027)
    8.8    Global Cardiometabolic Disease Market by Distribution Channel
        8.8.1    Hospital Pharmacies
            8.8.1.1    Market Share
            8.8.1.2    Historical Trend (2017-2021)
            8.8.1.3    Forecast Trend (2022-2027)
        8.8.2    Retail Pharmacies
            8.8.2.1    Market Share
            8.8.2.2    Historical Trend (2017-2021)
            8.8.2.3    Forecast Trend (2022-2027)
        8.8.3    Online Pharmacies
            8.8.3.1    Market Share
            8.8.3.2    Historical Trend (2017-2021)
            8.8.3.3    Forecast Trend (2022-2027)
        8.8.4    Others
    8.9    Global Cardiometabolic Disease Market by End Use
        8.9.1    Clinic
            8.9.1.1    Market Share
            8.9.1.2    Historical Trend (2017-2021)
            8.9.1.3    Forecast Trend (2022-2027)
        8.9.2    Hospital
            8.9.2.1    Market Share
            8.9.2.2    Historical Trend (2017-2021)
            8.9.2.3    Forecast Trend (2022-2027)
        8.9.3    Homecare Settings 
            8.9.3.1    Market Share
            8.9.3.2    Historical Trend (2017-2021)
            8.9.3.3    Forecast Trend (2022-2027)
    8.10    Global Cardiometabolic Disease Market by Region
        8.10.1    Market Share
            8.10.1.1    North America
            8.10.1.2    Europe
            8.10.1.3    Asia Pacific
            8.10.1.4    Latin America
            8.10.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Novartis AG
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Cardax, Inc.
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Novo Nordisk A/S
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Bayer AG
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Eli Lilly and Company
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    AstraZeneca PLC
            11.2.6.1    Company Overview
            11.2.6.2    Product Portfolio
            11.2.6.3    Demographic Reach and Achievements
            11.2.6.4    Certifications
        11.2.7    Boehringer Ingelheim International GmbH
            11.2.7.1    Company Overview
            11.2.7.2    Product Portfolio
            11.2.7.3    Demographic Reach and Achievements
            11.2.7.4    Certifications
        11.2.8    Others
12    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Cardiometabolic Disease Market: Key Industry Highlights, 2017 and 2027
2.    Global Cardiometabolic Disease Historical Market: Breakup by Type (USD Billion), 2017-2021
3.    Global Cardiometabolic Disease Market Forecast: Breakup by Type (USD Billion), 2022-2027
4.    Global Cardiometabolic Disease Historical Market: Breakup by Treatment (USD Billion), 2017-2021
5.    Global Cardiometabolic Disease Market Forecast: Breakup by Treatment (USD Billion), 2022-2027
6.    Global Cardiometabolic Disease Historical Market: Breakup by Dosage (USD Billion), 2017-2021
7.    Global Cardiometabolic Disease Market Forecast: Breakup by Dosage (USD Billion), 2022-2027
8.    Global Cardiometabolic Disease Historical Market: Breakup by Route of Administration (USD Billion), 2017-2021
9.    Global Cardiometabolic Disease Market Forecast: Breakup by Route of Administration (USD Billion), 2022-2027
10.    Global Cardiometabolic Disease Historical Market: Breakup by Distribution Channel (USD Billion), 2017-2021
11.    Global Cardiometabolic Disease Market Forecast: Breakup by Distribution Channel (USD Billion), 2022-2027
12.    Global Cardiometabolic Disease Historical Market: Breakup by End Use (USD Billion), 2017-2021
13.    Global Cardiometabolic Disease Market Forecast: Breakup by End Use (USD Billion), 2022-2027
14.    Global Cardiometabolic Disease Historical Market: Breakup by Region (USD Billion), 2017-2021
15.    Global Cardiometabolic Disease Market Forecast: Breakup by Region (USD Billion), 2022-2027
16.    North America Cardiometabolic Disease Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    North America Cardiometabolic Disease Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Europe Cardiometabolic Disease Historical Market: Breakup by Country (USD Billion), 2017-2021
19.    Europe Cardiometabolic Disease Market Forecast: Breakup by Country (USD Billion), 2022-2027
20.    Asia Pacific Cardiometabolic Disease Historical Market: Breakup by Country (USD Billion), 2017-2021
21.    Asia Pacific Cardiometabolic Disease Market Forecast: Breakup by Country (USD Billion), 2022-2027
22.    Latin America Cardiometabolic Disease Historical Market: Breakup by Country (USD Billion), 2017-2021
23.    Latin America Cardiometabolic Disease Market Forecast: Breakup by Country (USD Billion), 2022-2027
24.    Middle East and Africa Cardiometabolic Disease Historical Market: Breakup by Country (USD Billion), 2017-2021
25.    Middle East and Africa Cardiometabolic Disease Market Forecast: Breakup by Country (USD Billion), 2022-2027
26.    Global Cardiometabolic Disease Market Structure.

Key Questions Answered in the Report

In 2021, the global cardiometabolic disease market attained a value of nearly USD 111 billion.

The market is projected to grow at a CAGR of 3.90% between 2022 and 2027.

The market is estimated to witness healthy growth in the forecast period of 2022-2027 to reach USD 134.4 billion by 2027.

The major drivers of the market include the growing demand for a healthy lifestyle, higher consumption of fast food, rising usage of biomarkers for diagnostic and risk assessment procedures, increasing awareness and government initiatives, a growing number of patients adopting pharmaceuticals and therapeutics, increase in the proliferation of AI technology, and rise in the research and development (R&D) activities.

Rapidly changing lifestyles and a rise in the incidence of various diseases such as diabetes, high cholesterol, and other diseases are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on type, the market is segmented into chronic/congestive heart failure, hypertension, type 2 diabetes, and obesity.

The various treatments in the market are angiotensin converting enzyme (ACE) inhibitors, diuretics, glucophage, and liposuction.

Based on dosage, the market is divided into tablet and injection.

Based on route of administration, the market includes oral and intravenous.

The several distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.

The end-uses of the market are clinic, hospital, and homecare settings.

The major players in the industry are Novartis AG, Cardax, Inc., Novo Nordisk A/S, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, and Boehringer Ingelheim International GmbH, among others.

Analyst Review

The global cardiometabolic disease market attained a value of USD 111 billion in 2021, driven by the rise in various diseases, such as diabetes, high cholesterol, and cardiac disorders. Aided by the rise in research and development (R&D) activities and rapidly changing lifestyles, the market is expected to witness further growth in the forecast period of 2022-2027, growing at a CAGR of 3.90%. The market is projected to reach USD 134.4 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the market is segmented into chronic/congestive heart failure, hypertension, type 2 diabetes, and obesity. The various treatments in the market are angiotensin converting enzyme (ACE) inhibitors, diuretics, glucophage, and liposuction. Based on dosage, the market is divided into tablet and injection. Based on route of administration, the market includes oral and intravenous. The several distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others. The end-uses of the market are clinic, hospital, and homecare settings. The major regional markets for cardiometabolic disease are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the cardiometabolic disease market are Novartis AG, Cardax, Inc., Novo Nordisk A/S, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, and Boehringer Ingelheim International GmbH, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER